@article{JTD4138,
author = {Weisan Zhang and Qian Liu and Xifeng Dong and Ping Lei},
title = {A meta-analysis comparing hyperfractionated vs. conventional fractionated radiotherapy in non-small cell lung cancer},
journal = {Journal of Thoracic Disease},
volume = {7},
number = {3},
year = {2015},
keywords = {},
abstract = {Background: Lung cancer is the leading cause of cancer-related mortality. Non-small cell lung cancer (NSCLC) accounts for most lung cancer and carries a 5-year survival rate of 15%. The squamous cell carcinoma, large cell carcinoma, and adenocarcinoma are the most common types of NSCLC. The data on long term use of hyperfractionated radiotherapy (HRT) in NSCLC treatment is lacking. We performed a meta-analysis, based on published randomized trials to compare HRT [continuous hyperfractionated accelerated radiotherapy (CHART)/continuous hyperfractionated accelerated radiotherapy weekend less (CHARTWEL)] vs. conventional fractionated (CF) radiotherapy in the treatment of NSCLC.
Methods: A systematic search through the bibliographic databases, PubMed, Google Scholar and Cochrane Library was performed till December 2013.
Results: Of 63 studies identified, 3 studies were analyzed. All were randomized studies and included 1,005 patients in total. The pooled results of the studies showed that HRT did not improve overall survival (OS) of patients suffering from NSCLC compared to CF after 2 years (OR, 1.29; 95% CI, 0.98-1.71; P=0.16) and 3 years (OR, 0.55; 95% CI, 0.34-0.87; P=0.22) which was statistically significant. HRT was no better than CF in controlling tumour (OR, 1.40; 95% CI, 1.03-1.91). No significant difference in metastasis free survival (OR, 1.08; 95% CI, 0.83-1.39) and late dysphagia (OR, 1.48; 95% CI, 0.75-2.92) were observed between the two groups.
Conclusions: The results of the present meta-analysis showed that HRT was not significantly better to conventional radiotherapy in NSCLC treatment.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/4138}
}